Laddar...
Oral Administration System Based on Meloxicam Nanocrystals: Decreased Dose Due to High Bioavailability Attenuates Risk of Gastrointestinal Side Effects
Meloxicam (MLX) is widely applied as a therapy for rheumatoid arthritis (RA); however, it takes far too long to reach its peak plasma concentration for a quick onset effect, and gastrointestinal toxicity has been observed in RA patients taking it. To solve these problems, we designed MLX solid nanop...
Sparad:
| I publikationen: | Pharmaceutics |
|---|---|
| Huvudupphovsmän: | , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
MDPI
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7238067/ https://ncbi.nlm.nih.gov/pubmed/32244754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics12040313 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|